Which antiarrhythmic drugs are contraindicated in atrial fibrillation with rapid ventricular response and why?

Contraindicated Antiarrhythmic Drugs in Atrial Fibrillation with Rapid Ventricular Response

In atrial fibrillation with rapid ventricular response (AFib RVR), AV nodal blocking agents (adenosine, calcium channel blockers, digoxin, and beta-blockers) are absolutely contraindicated in patients with pre-excitation syndromes (Wolff-Parkinson-White), and class IC agents (flecainide, propafenone) are contraindicated in patients with structural heart disease, coronary artery disease, or heart failure. 1, 2

Critical Contraindications by Clinical Context

Pre-Excitation Syndromes (WPW)

In patients with AFib RVR and an accessory pathway:

• Absolutely avoid: Adenosine, diltiazem, verapamil, digoxin, and beta-blockers 1, 2, 3
• Mechanism of harm: These AV nodal blocking agents selectively slow conduction through the AV node without affecting the accessory pathway, causing preferential conduction through the bypass tract, which can precipitate ventricular fibrillation 2, 4
• Appropriate agents: Procainamide is the drug of choice; propafenone, flecainide, and disopyramide are alternatives 2, 4

Structural Heart Disease

Class IC agents (flecainide and propafenone) must be avoided in patients with: 5, 6, 7

• Coronary artery disease (active ischemia or history of MI)
• Heart failure with reduced ejection fraction (LVEF <40%)
• Significant left ventricular hypertrophy (LV wall thickness ≥1.4 cm)
• Mechanism of harm: These agents increase the risk of ventricular arrhythmias and sudden death in patients with structural heart disease 8, 6

Additional Class IC Contraindications

Flecainide and propafenone should also be avoided in: 6

• Advanced AV block (second- or third-degree) or significant conduction system disorders
• Left bundle branch block or right bundle branch block with left hemiblock
• Severe hepatic or renal impairment (CrCl <35 mL/min)
• Brugada syndrome (risk of sudden death from ventricular fibrillation) 9

Class III Agent Contraindications

Sotalol

Avoid sotalol in patients with: 8, 6

• Pre-existing QTc prolongation (>500 ms) or congenital long QT syndrome
• High-degree AV conduction disorders
• Severe renal impairment (CrCl <40 mL/min)
• Significant LV systolic dysfunction (LVEF <40%)
• High-risk patients for torsades de pointes: Women >65 years on diuretics, renal insufficiency, hypokalemia, hypomagnesemia 8

Dofetilide

Contraindicated when: 10, 9

• Creatinine clearance <20 mL/min
• QTc >500 ms or risk factors for torsades de pointes
• Concurrent use of other QT-prolonging drugs 5

Conduction System Disease

All antiarrhythmic drugs are contraindicated in patients with: 10, 6, 7

• Advanced sinus node dysfunction
• High-degree AV nodal disease
• Unless: A functioning pacemaker or implantable defibrillator is present

Critical Safety Principle for Class IC Agents

When class IC drugs are used, they MUST be combined with an AV nodal blocking agent (beta-blocker or non-dihydropyridine calcium channel blocker) 9, 8, 6. This prevents the risk of AF organizing into atrial flutter with 1:1 AV conduction, which can cause dangerously rapid ventricular rates and precipitate ventricular tachycardia.

Common Pitfalls to Avoid

1. Never use digoxin, diltiazem, or verapamil in pre-excited AFib - this is a potentially fatal error 1, 2

2. Do not assume "no structural heart disease" in patients >50 years - consider formal ischemia assessment before initiating class IC agents 6

3. Monitor QRS widening with class IC agents - discontinue if QRS exceeds 150% of baseline or increases >25% 10, 6

4. Check renal function before sotalol or dofetilide - both require dose adjustment or are contraindicated with renal impairment 8, 6

5. Avoid combining multiple QT-prolonging drugs - check www.torsades.org for drug interactions 8, 9